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Abstract
Minimal change disease (MCD) is an important cause of nephrotic syndrome
and is characterized by massive proteinuria and hypoalbuminemia, resulting in
edema and hypercholesterolemia. The podocyte plays a key role in filtration
and its disruption results in a dramatic loss of function leading to proteinuria.
Immunologic disturbance has been suggested in the pathogenesis of MCD.
Because of its clinical features, such as recurrent relapse/remission course,
steroid response in most patients, and rare familial cases, a genetic defect has
been thought to be less likely in MCD. Recent progress in whole-exome
sequencing reveals pathogenic mutations in familial cases in steroid-sensitive
nephrotic syndrome (SSNS) and sheds light on possible mechanisms and key
molecules in podocytes in MCD. On the other hand, in the majority of cases,
the existence of circulating permeability factors has been implicated along with
T lymphocyte dysfunction. Observations of benefit with rituximab added B cell
involvement to the disease. Animal models are unsatisfactory, and the
humanized mouse may be a good model that well reflects MCD
pathophysiology to investigate suggested “T cell dysfunction” directly related to
podocytes  . Several candidate circulating factors and their effects onin vivo
podocytes have been proposed but are still not sufficient to explain whole
mechanisms and clinical features in MCD. Another circulating factor disease is
focal segmental glomerulosclerosis (FSGS), and it is not clear if this is a distinct
entity, or on the same spectrum, implicating the same circulating factor(s).
These patients are mostly steroid resistant and often have a rapid relapse after
transplantation. In clinical practice, predicting relapse or disease activity and
response to steroids is important and is an area where novel biomarkers can be
developed based on our growing knowledge of podocyte signaling pathways.
In this review, we discuss recent findings in genetics and podocyte biology in
MCD.
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Introduction
Minimal change disease (MCD) is characterized by massive 
proteinuria without histological evidence of immune-mediated 
damage in the glomeruli. The glomerular podocyte plays a key role 
in filtration and its loss of function results in loss of protein, mainly 
albumin or smaller proteins, into the urine with high selectivity1. 
Proteinuria in MCD is typically reversible with corticosteroid 
therapy2. T cell dysfunction and circulating factors have long been 
implicated as a cause of the podocyte dysfunction in MCD3, but 
their nature still remains to be elucidated.
Recent progress in genetics and cell biology has revealed the 
molecular mechanisms of dysfunction in podocytes4. These find-
ings give us clues to focus on target molecules on the podocyte to 
deduce what those circulating factors may be. At the same time, 
we can utilize those molecules as biomarkers not only as a diag-
nostic tool but also in predicting the disease activity or prognosis. 
This allows us to administer more accurate and precise treatment to 
patients with MCD while minimizing side effects caused by drugs.
Alongside MCD as one circulating factor disease is a subset of 
patients with the histological finding of focal segmental glomeru-
losclerosis (FSGS). These patients are mostly steroid resistant, and 
therefore the term steroid-resistant nephrotic syndrome (SRNS) is 
also used here. These patients often have a rapid relapse after trans-
plantation, indicating another circulating factor disease. It is likely 
that at least a subset of patients with MCD progress to FSGS/SRNS, 
with a consistent circulating factor in both. The most compelling 
evidence for this is the observation that patients with initial steroid 
sensitivity (assumed to be MCD at that stage) who over subsequent 
years develop steroid resistance/FSGS, and renal failure, have a 
90% chance of post-transplant disease recurrence – the archetypal 
manifestation of circulating factor disease5. In this article, known 
pathogenesis and mechanisms underlying MCD are reviewed.
Clinical features of MCD
MCD is the most common cause of nephrotic syndrome in 
children6 and around 15–20% of cases in adults7, and is charac-
terized by massive proteinuria and hypoalbuminemia, resulting 
in edema and hypercholesterolemia. Histological findings of the 
disease in glomeruli are typically normal by light microscopy and 
only electron microscopy shows effacement of podocyte foot proc-
esses without electron-dense immune deposits8. These manifesta-
tions are typically reversible with the use of corticosteroid therapy 
in steroid-sensitive nephrotic syndrome (SSNS), so that progressive 
loss of renal function is rare.
The incidence of MCD in childhood is twofold higher in boys, with 
a prevalence that is inversely proportional to age. Relapse occurs 
in 50–80% of patients, and recurrent relapse tends to lessen after 
adolescence9. A genetic defect cannot explain these phenomena in 
MCD.
Genetics in MCD
Pathogenic mutations in MCD
Familial cases are rather rare in MCD, therefore the genetic 
background of SSNS is largely unknown, while 23.6% of SRNS 
cases10 and 29.5% of familial SRNS cases11 are caused by gene 
mutation. More than 24 genes are currently known to be pathogenic 
in SRNS12 and have already been clinically utilized in practice in 
SRNS cases.
Recently, using whole-exome sequencing, several mutations were 
found in pedigrees with SSNS, which shed light on new mecha-
nisms of podocyte disruption in MCD. Epithelial membrane pro-
tein 2 (EMP2) is known to regulate the amount of caveolin-113, 
which contributes to endocytosis and the transcytosis of choles-
terol and albumin14. Lipopolysaccharide (LPS)-induced caveolin-1 
phosphorylation was reported to lead to the increase of transcellular 
permeability15.
More recently, recessive mutations in the KANK gene were iden-
tified in familial SSNS and in sporadic SRNS cases16. Kidney 
ankyrin repeat-containing protein (KANK) family proteins have 
essential roles in podocyte/nephrocyte function and regulate Rho 
GTPase activity. KANK2 interacted with Rho GDP dissociation 
inhibitor alpha (ARHGDIA), a known regulator of Rho GTPases 
in podocytes found to be dysfunctional in SRNS17. Knockdown of 
KANK2 in cultured podocytes increased active GTP-bound RHOA 
and decreased migration.
In these cases, we might have evidence of overlap of SSNS and 
SRNS. Also, it is important to know the mechanisms of how 
corticosteroid and immunosuppressants have their effect on neph-
rotic syndrome caused by single gene mutation.
T cell dysfunction in MCD
T cell dysfunction has long been postulated and many types of 
cytokines have been investigated. One of the difficulties in exam-
ining a hypothesis that immunological disruption underlies MCD 
in the laboratory is the lack of an animal model that reflects the 
pathophysiological mechanism. Haddad et al. employed unique 
methods and established a nephrotic syndrome model by inject-
ing CD34+ peripheral stem cells obtained from FSGS and MCD 
patients18 rather than injecting the supernatant of T cells or 
peripheral blood mononuclear cells (PBMCs) obtained from the 
patients19. The injected cells successfully induced the engraftment 
of human CD45 leukocytes in the thymus, and only the injection 
of CD34+ stem cells from patients induced albuminuria. Interest-
ingly, stem-cell-injected mice did not have CD3+ mature T cells, 
suggesting that the cells responsible for the pathogenesis of idi-
opathic nephrotic syndrome are more likely to be immature 
differentiating cells rather than mature peripheral T cells. Naïve 
T cells (Th0s) have been focused on to investigate the difference 
in DNA methylation in MCD patients20. The change in DNA meth-
ylation patterns from remission to relapse occurs predominantly 
in Th0s. Epigenetic involvement in the pathogenesis of minimal 
change nephrotic syndrome in T cells has also been suggested in a 
report showing that nuclear factor related to kappaB binding pro-
tein (NFRKB) was highly expressed in the nuclear compartment in 
T lymphocytes of MCD patients during relapse and that NFRKB 
promotes hypomethylation of genomic DNA in HEK cells trans-
fected with NFRKB expression plasmid21.
Another T cell dysfunction is a Th17 skew in MCD22,23 (Figure 1). 
Patients with SSNS demonstrated after corticosteroid treatment 
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that the Th17/regulatory T cell (Treg) balance returned to normal24. 
More recently, it was reported that Th17 cells are strong candidate 
drivers for steroid resistance in immune diseases and have selective 
attenuation by cyclosporine A25. This could be utilized to predict 
steroid response in early stages of nephrotic syndrome onset by test-
ing peripheral Th17 levels.
Rituximab and B cell dysfunction
A potential close pathophysiological relationship between MCD 
and chronic lymphoid neoplasms such as Hodgkin and non- 
Hodgkin lymphoma has been known since the 1950s, supporting 
a potential role for B cells in the pathogenesis of MCD (Figure 1). 
A significant association of HLA-DQA1 (a major histocompatibil-
ity complex [MHC] class II) missense coding variants with SSNS 
recently suggested the possible role of an immune response and 
the implication of B cells in the pathogenesis of MCD26.
Though the accurate mechanism by which rituximab, a mono-
clonal antibody against CD20, induces remission in MCD patients 
remains uncertain, recent observations of the effect of rituximab 
on complicated refractory SSNS27–29 suggests a pathophysiological 
role for B cells in MCD30,31 (Figure 1). B cell depletion by rituxi-
mab resets and suppresses B cell and T cell interactions and keeps 
the Th17/Treg balance normal, which may lead to sustainable 
remission32,33. On the other hand, a direct role for rituximab on 
podocyte cytoskeleton stabilization was suggested: rituximab pre-
vents disruption of the actin cytoskeleton in cultured normal human 
podocytes that have been exposed to FSGS patient sera in a sphin-
gomyelin phosphodiesterase acid-like 3b-dependent manner34.
Circulating factors and podocyte cell biology in MCD
A direct test of “circulating factor” activity is to expose human 
podocytes in culture to active human disease plasma and examine 
Figure 1. Scheme of lymphocyte dysfunction and circulating factors in minimal change disease (MCD). By immune trigger such as 
viral infection, vaccination, and exposure to allergen, antigen-presenting cells and memory B cells present antigen to T lymphocyte. These 
cells are stimulated to secrete circulating factors in MCD. Rituximab depletes B cells and induces remission; on the other hand, rituximab 
has an effect on cytoskeleton stability of podocytes and blocks albumin permeability. Th17 skew in MCD may cause steroid resistance 
and cyclosporine A selectively attenuates Th17. Abbreviations: APCs, antigen presenting cells; CysA, cyclosporine A; CF, circulating 
factor; IL17, interleukin 17; Th17, helper T subset 17; TNF-a, tumor necrosis factor alpha.
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the direct cellular effects on this target cell. It has been shown using 
this method that nephrotic plasma alters slit diaphragm-dependent 
signaling and translocates nephrin, podocin, and CD2-associated 
protein in cultured human podocytes35. This indicated that there is a 
certain factor increasing or missing in MCD disease plasma.
Hemopexin
Hemopexin (Hpx) is a circulating plasma protease that is synthe-
sized in the liver. The active isoform of Hpx is increased in children 
with MCD36. In vitro, podocytes showed dramatic reorganization of 
actin with loss of stress fibers after Hpx treatment37. The Hpx effect 
on actin is dependent on nephrin followed by RhoA activation and 
protein kinase B phosphorylation in the downstream intracellular 
signaling pathway. The effects were reversible and were inhibited 
by pre-incubation with healthy human plasma or serine protease 
inhibitors. Though the mechanisms of Hpx activation in the disease 
are unclear, LPS and tumor necrosis factor (TNF)-α are indicated 
as possible triggers to activate Hpx in MCD38.
PAR1 signaling axis and VASPp, or suPAR
Because it has serine protease activity39, Hpx may act via the fam-
ily of protease-activated receptors. There are also matrix metal-
loproteinases among those proteins that have Hpx homology 
domains. Recent studies investigated the possibility of a matrix 
metalloproteinase–protease-activated receptor 1 (PAR1) signal-
ing axis40. It was recently reported that proteases present in neph-
rotic plasma obtained from patients with FSGS can activate PAR1, 
leading to the podocin-dependent phosphorylation of the actin-
associated protein vasodilator-stimulated phosphoprotein (VASP) 
in human podocytes and increased cell migration, suggesting a 
novel role for proteases and PARs in the pathogenesis of FSGS41,42. 
Although the exact component(s) of FSGS plasma that causes this 
response remains unknown, the soluble urokinase plasminogen 
activator receptor (suPAR) has been identified as a potential circu-
lating factor in FSGS via activation of β3 integrin in podocytes and 
promotes cell motility43–45. However, correlation of disease activity 
with suPAR levels has been inconsistent in subsequent reports46,47. 
Urinary suPAR was increased in MCD relapse, but it is thought 
it may simply be a surrogate for proteinuria48. These factors are 
found in FSGS but are potentially also relevant to MCD; this needs 
experimental verification.
CD80 
CD80 (B7-1) is a T cell co-stimulatory molecule involved in antigen 
processing that is also unexpectedly expressed on podocytes in cer-
tain experimental and clinical disease states. Podocyte CD80 acti-
vation through Toll-like receptor (TLR) 3 and 4 by LPS, independent 
of T cells, causes proteinuria and foot process effacement49.
Urinary CD80 levels are increased in MCD during relapse but are 
not increased in FSGS patients or MCD patients in remission50. 
Sera from MCD patients in relapse, but not in remission, stimulated 
CD80 expression in cultured podocytes51. The factor(s) in patients’ 
serum that stimulates podocytes is unknown. Most recently, it was 
reported that no significant up-regulation of podocyte CD80 was 
detected in MCD and FSGS patients’ biopsies compared with con-
trols using different primary antibodies and immunohistochemical 
assays, suggesting further confirmation is needed with CD80 in 
MCD52.
TNF-α 
TNF-α is suggested to be one of the circulating factors that exists 
in patient plasma of post-transplant recurrent FSGS53,54. The effect 
on the podocyte was actin cytoskeleton disruption and activation 
of β3 integrin. In MCD, it has been suggested that TNF-α syn-
thesis in peripheral mononuclear cells from relapse is increased55. 
Genome-wide DNA methylation analysis was performed in naïve 
T helper cells both in relapse and in remission of MCD20 and it was 
found that the promoter region of TNF-α from relapse has a signifi-
cant reduction in DNA methylation compared to that from remis-
sion in the same individuals, indicating predisposition of TNF-α 
synthesis in relapse in MCD [personal communication, Dr Yasuko 
Kobayashi].
Summarizing the data, an excess factor or missing/imbalance of 
factors in relapse plasma could be the primary cause of MCD, and 
interesting candidates with biological plausibility are Hpx, suPAR, 
and TNF-α. PAR1 or uPAR and β3 integrin are therefore poten-
tially activated by circulating factors, and VASP-p is in the pathway 
downstream of PAR1 or integrins. CD80 is a product of podocyte 
stimulation by circulating factors. Reorganization of actin by Hpx 
is dependent on nephrin. The structural changes in actin result in 
foot process effacement and increase of permeability, which is the 
core feature in the disease.
The circulating factors might be secreted by peripheral blood cells 
such as T or B cells by mesangial or endothelial cells in a paracrine 
manner or by the podocyte itself in an autocrine manner.
Conclusion 
Pathogenic gene mutation analysis in familial MCD has started to 
reveal insights into underlying mechanisms of pathophysiology 
in the podocyte, such as endocytosis or Rho GTPase, related to 
permeability.
We have less evidence of circulating factor activity or from genetic 
disease in MCD compared to FSGS, perhaps because of less disease 
severity and lower availability of patient samples in MCD. In terms 
of circulating factor diseases, findings in FSGS can be examined in 
relation to MCD. A humanized mouse model might give us a good 
tool to investigate T cell dysfunction directly related to podocytes.
There are several candidates for biomarkers to predict disease 
activity or steroid response that allow us to choose precise and 
acceptable treatment for each individual patient while reducing the 
side effects of long-term treatment.
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New components might be inducible targeting of a specific mol-
ecule that is involved in the pathogenesis of MCD both for 
screening and for treatment.
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